What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GH-axis blend (Tesamorelin + Ipamorelin), 15 mg total
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Tesamorelin + Ipamorelin Blend (15 mg) inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
The Tesamorelin + Ipamorelin blend applies the same dual-pathway GH-axis strategy as the canonical CJC-1295 + Ipamorelin combination but substitutes Tesamorelin as the GHRH-receptor agonist. The substitution has two practical implications: Tesamorelin is FDA-approved as a finished drug (Egrifta for HIV-associated lipodystrophy), giving it a regulatory and clinical pedigree that CJC-1295 lacks; and Tesamorelin's half-life and pharmacokinetic profile differ slightly from CJC-1295 no-DAC, producing somewhat different GH-release kinetics in dual-pathway protocols. Both formulations preserve the core dual-pathway mechanism (GHRH-receptor activation plus GHSR-receptor activation converging on somatotroph GH release) that produces the additive effect. PeptideXpo supplies the Tesamorelin + Ipamorelin blend as a co-lyophilized 15 mg total-mass vial at ≥99.0% HPLC purity for each component. The standard split is 10 mg Tesamorelin + 5 mg Ipamorelin, reflecting the higher mass-equivalent dosing typically used for Tesamorelin in compounding workflows. Custom ratios are available through OEM service. The release packet certifies both component purities and the actual ratio in the released vial.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.
Frequently asked questions
Tesamorelin is typically dosed at higher mass-equivalent levels than CJC-1295 in published compounding-pharmacy protocols because of differences in receptor-binding affinity per mg between the two GHRH-receptor agonists. The 10+5 mg blend ratio matches the typical mass-equivalent ratio used in dual-pathway protocols based on Tesamorelin rather than CJC-1295. Custom ratios are available via OEM service if a specific research or clinical protocol requires a different split, the standard 10+5 is the conservative default that aligns with the most-published combination dosing in this family.
Tesamorelin (Egrifta) is the only FDA-approved GHRH-analog in the GH-axis family, which gives the bulk active a regulatory pedigree the other components lack. Ipamorelin is not on the 503A bulks list at the time of writing. The blend's compounding eligibility therefore depends on the destination market's current regulatory posture for each component individually and for the combination, pharmacy buyers should verify the eligibility against their state-board requirements at the time of dispense. For the 503A vs 503B distinction more broadly, see our [compounding pathway guide](/insights/503a-vs-503b-compounding-pharmacy-peptides).
Related peptides
44-mer
GHRH analog · approved for HIV-associated lipodystrophy
Ghrelin / GHSR pathway GH-release peptide
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
